Endologix Inc., said to be the biggest company dedicated to endovascular treatment of abdominal aortic aneurysms (AAAs), saw its share price plummet to a 52-week low after it announced it was temporarily holding off shipments of its AFX AAA repair system while it resolves a manufacturing issue that was causing damage to the graft material in some sizes of the device. Sales of AFX account for around 60%-65% of Endologix's total revenue.
The firm's stock price fell to $5.26 amidst heavy volume trading on the Nasdaq on Dec. 27. This represents a 27% drop from $7.19, the closing price on Dec. 23,...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?